Search Results: Prevention, Detection & Risk (8 results)
MRI Screening in Men at High Risk of Developing Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/260/screening-in-men-at-high-risk-of-developing-prostate-cancer
Prevention
Screening using MRI for men at risk of developing prostate cancer
This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.
Men at High Genetic Risk for Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress
Prevention
People at high risk for prostate cancer due to an inherited mutation
This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.
Blood Markers of Early Pancreas Cancer
https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer
Prevention
Screening for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.
The purpose of this study is to try to find markers of early pancreatic cancer for screening for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation
https://www.facingourrisk.org/research-clinical-trials/study/121/screening-for-pancreatic-cancer-in-patients-with-an-inherited-brca1-brca2-palb2-or-atm-mutation
Prevention
Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)
https://www.facingourrisk.org/research-clinical-trials/study/138/validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US.
A Pancreatic Cancer Screening Study for High Risk Individuals
https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people
Prevention
The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.
Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer.
Pancreatic Cancer Early Detection Program
https://www.facingourrisk.org/research-clinical-trials/study/20/pancreatic-cancer-early-detection
Prevention
This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + PALB2
3 results
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT ID: NCT02478892 (https://classic.clinicaltrials.gov/show/NCT02478892)
MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT ID: NCT05608694 (https://classic.clinicaltrials.gov/show/NCT05608694)
Blood Markers of Early Pancreas Cancer
NCT ID: NCT03568630 (https://classic.clinicaltrials.gov/show/NCT03568630)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.